Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors

Monoclonal antibodies that inhibit the programmed cell death protein 1 axis (anti-PD-1/PD-L1) are part of a new pharmacological strategy aimed at reinforcing the immune response to cancer. Despite the success in several cancer types, a significant percentage of patients do not benefit from treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochimica et biophysica acta. Reviews on cancer 2021-01, Vol.1875 (1), p.188463-188463, Article 188463
Hauptverfasser:	Del Re, Marzia, van Schaik, Ron H.N., Fogli, Stefano, Mathijssen, Ron H.J., Cucchiara, Federico, Capuano, Annalisa, Scavone, Cristina, Jenster, Guido W., Danesi, Romano
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - blood Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - blood B7-H1 Antigen - genetics B7-H1 Antigen - immunology Cancer Exosomes Extracellular vesicles Extracellular Vesicles - genetics Humans Immune Checkpoint Inhibitors - therapeutic use Immune-checkpoint inhibitors Immunotherapy - methods Liquid biopsy Neoplasms - blood Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy PD-1/PD-L1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - blood Programmed Cell Death 1 Receptor - genetics Programmed Cell Death 1 Receptor - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!